Thus, the study of two syngeneic mouse models of MDS and AML based on co-mutation of IDH2/SRSF2 or IDH2/FLT3 further supported the sensitivity of IDH2-mutant AML cells to PARP inhibitors [177]. Here, FLT3 is linked to acute myeloid leukemia.